In 2017, the United States, followed by (the leading 15 countries from) Western Europe, had that largest share of pharmaceutical revenue globally. For comparison, Australia had one of the lowest single shares among the listed countries. The data shows that the United States held 33 percent of global pharmaceutical revenue. The pharmaceutical industry is composed of various actors responsible for the discovery, development, and distribution of drugs and medicines.

The global pharma industry

The worldwide pharmaceutical market was recently valued at over 1.14 trillion U.S. dollars. Trends suggest that the pharmaceutical market globally is on the increase. In recent years Pfizer had the largest amount of global prescription sales; however, Roche had the highest research and development spending. Research and development is important for creating new, innovative pharmaceuticals, since branded products are under the threat of patent expiration and generic competition after a certain amount of years.

Leading therapeutic classes

Based on therapeutic classes, at this moment, the largest shares of pharmaceuticals sales globally are attributable to oncologics and pain management drugs. Among all therapeutic classes, Humira, Eliquis and Revlimid were the top three drugs sold. Among oncologics, the top pharmaceutical sales sector, Revlimid (marketed by Celgene) generated the most revenue in recent years.

The global pharmaceutical market is expected to grow at a CAGR of 5% during 2011-2017, exceeding sales worth US$ 1.1 Trillion by 2017. This market, however, is expected to undergo a number of transitions which would impact the course of its growth. These transitions include a shift of growth from the developed to the emerging markets, an increasing focus on biopharmaceuticals compared to small molecule drugs and an increasing preference for generics compared to their branded versions. As a result of these transformations; the need for a user friendly, robust and comprehensive pharmaceutical market intelligence has become imperative for investors, researchers, consultants, marketing strategists, and all those who are planning to foray into the pharmaceutical market in some form or the other.

IMARC Group, one of the world’s leading research and advisory firms, introduces a new and revolutionary way to understand and evaluate the global pharmaceutical market with its Microsoft Excel based report entitled “Global Pharmaceutical Market Report & Forecast: 2012-2017”. This report provides an analytical and statistical insight into the global pharmaceutical market. The study, which has been undertaken using desk based as well as primary market research has analyzed the following aspects of the global pharmaceutical market.

What We Have Achieved in This Report?

Regions Covered: Global, North America, Europe, Asia Pacific, Latin America & Caribbean and Middle East & Africa

Countries Covered in Each Region

North America: United States and Canada

Europe: Germany, France, Italy, Spain, United Kingdom, Russia, Turkey, Netherlands, Poland, Greece, Belgium, Switzerland, Austria, Sweden, Portugal, Hungary, Romania, Denmark, Czech Republic, Finland, Ireland, Norway, Slovakia, Bulgaria, Croatia, Slovenia, Lithuania, Latvia, Luxembourg and Estonia

Asia Pacific: Japan, China, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Pakistan, Vietnam, Bangladesh, Hong Kong, New Zealand, Malaysia and Singapore

Latin America & Caribbean:Brazil, Mexico, Venezuela, Argentina, Puerto Rico, Colombia, Chile, Ecuador, Peru, Dominican Republic and Uruguay

Middle East & Africa: South Africa, Egypt, Saudi Arab, Algeria, Morocco, United Arab Emirates Lebanon, Tunisia, Jordan and Kuwait

Focus of the Analysis:

• Historical sales performance (2007-2011) for each country
• Historical sales performance (2007-2011) for each region
• Sales forecast (2012-2017) for each country
• Sales forecast (2012-2017) for each region
• Sales performance of key manufacturers for each country (2007-2011)
• Sales performance of key therapeutic areas for each country (2007-2011)
• Country wise sales breakup for each region (2007-2011)
• Country wise sales breakup forecast for each region (2012-2017)

Key Questions Answered;

• What was the historical performance of the global pharmaceutical market?
• Which are the key regions and countries in the global pharmaceutical market?
• Which are the largest pharmaceutical markets in the world?
• Which are the fastest growing pharmaceutical markets in the world?
• Which markets are expected to witness the slowest growth in the coming years?
• Which countries represent the key markets for each region?
• What has been the performance of various therapeutic classes in each country?
• Who are the top pharmaceutical manufacturers in each country?
• What are the market shares of the top pharmaceutical manufacturers in each country?

Why You should Buy This Report?

• To gain a comprehensive understanding on the historical, current and future pharmaceutical market trends across 70 countries in 6 regions.
• To identify potential regions, countries, therapeutic areas, partners and competitors for market entry and expansion plans.
• As a tool for developing investment strategies by identifying the biggest winners and losers across various regions and countries.
• To ensure a successful M&A and partnership strategy by identifying therapeutic areas and companies with the most promising outlook.

The global pharmaceutical market has experienced significant growth in recent years. For 2024, the total global pharmaceutical market was estimated at around *** trillion U.S. dollars. This is an increase of roughly *** billion dollars compared to 2023. Global pharmaceutical markets Globally, the United States is by far the leading market for pharmaceuticals, followed by other developed countries and emerging markets. Emerging markets can include middle and low-income countries such as Brazil, India, Russia, Colombia and Egypt, to name a few. Despite increasing revenues globally, the Latin American region accounts for the lowest share of the global pharmaceutical market’s revenues. Top pharmaceuticals globally The top pharmaceutical products sold globally include Humira, Eliquis and Revlimid. Oncology is the op therapeutic area for drug sales globally, and it is expected to show the largest growth over the next years. It is followed by drug spending for autoimmune diseases and diabetes. During the height of the COVID-19 pandemic, Comirnaty was the world's top revenue generating pharmaceutical product.

This statistic shows the worldwide forecast of pharmaceutical sector growth between 2017 and 2060, by select country. The forecast predicts that between 2017 and 2060 the pharmaceutical sector worldwide will grow by 317 percent, with the biggest growth forecast given for India with 754 percent.

This statistic depicts the growth in global pharmaceutical research and development spending from 2017 to 2030. In 2024, the pharmaceutical industry expenditure on research and development increased *** percent.

This statistic displays the gross value added in the pharmaceutical industry worldwide from 2006 to 2017. In 2017, the gross value added by the industry totaled 532 billion U.S. dollars. The pharmaceutical industry employs directly around 5.5 million people across the globe.

This statistic describes the global pharmaceutical sales in from 2020 to 2024, sorted by regional submarkets. For 2024, total pharmaceutical sales in the United States was estimated to reach around *** billion U.S. dollars. World pharmaceutical sales by regionThe pharmaceutical industry is best known for manufacturing pharmaceutical drugs which aim to diagnose, cure, treat, or prevent diseases. The pharmaceutical sector represents a huge industry, with the global market being worth around *** trillion U.S. dollars. Among the best known top global pharmaceutical companies are Pfizer, Merck and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Accordingly, North America and Europe are still among the largest global submarkets for pharmaceuticals. In 2024, the United States was still the largest single pharmaceutical market, generating more than *** billion U.S. dollars of revenue. Europe was responsible for generating around *** billion U.S. dollars. These two markets, together with Japan, Canada and Australia, form the so-called established (or developed) markets. The rest of the global pharmaceutical revenue is mainly from emerging markets, which include countries like China, Russia, Brazil and India. In fact, these emerging markets show the fastest increase in pharmaceutical sales. Latin America is the world region with the highest predicted compound annual growth rate until 2028.

CH: Pharmaceutical Industry: Export Market Share data was reported at 12.973 % in 2020. This records a decrease from the previous number of 13.281 % for 2019. CH: Pharmaceutical Industry: Export Market Share data is updated yearly, averaging 10.752 % from Dec 1996 (Median) to 2020, with 25 observations. The data reached an all-time high of 13.565 % in 2016 and a record low of 8.887 % in 2003. CH: Pharmaceutical Industry: Export Market Share data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Switzerland – Table CH.OECD.MSTI: Trade Statistics: OECD Member: Annual.

In Switzerland, the Business Enterprise sector comprises private enterprises only. Public enterprises are included in the Government sector.

From 2000, the Government sector no longer includes the telecommunications companies that have been privatised (Swisscom).

From 2017 onwards, GBARD data are derived from a funder-based approach (performer-based approach before 2017). The Swiss contribution to the European Space Agency is allocated to the space objective in GBARD as of 2006, while it was before included in non-oriented research programmes. From 1998, the Federal Office of Agriculture and its research institutes no longer break down their R&D by socio-economic objective but group all under 'Agriculture'. For GBARD this results in a break in series for both Agriculture and Health objectives, where half of the funds previously declared under Health are now declared under Agriculture. Also in 1998, the telecommunications field of the Federal Post office has become the private enterprise Swisscom which is no longer included under the Infrastructure objective in GBARD. Before 1994, GBARD did not include the public sector financed R&D mandates.

Slovakia SK: Pharmaceutical Industry: Export Market Share data was reported at 0.081 % in 2020. This records an increase from the previous number of 0.074 % for 2019. Slovakia SK: Pharmaceutical Industry: Export Market Share data is updated yearly, averaging 0.089 % from Dec 1996 (Median) to 2020, with 25 observations. The data reached an all-time high of 0.179 % in 1997 and a record low of 0.068 % in 2017. Slovakia SK: Pharmaceutical Industry: Export Market Share data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Slovakia – Table SK.OECD.MSTI: Trade Statistics: OECD Member: Annual.

For the Slovak Republic, data before 1994 refer to the Research and Development Base (RDB) and cover the whole activity of institutions and not only R&D. Defence R&D was totally excluded until 1997 and only partially included thereafter.

Since 2002, a new budget classification compatible with COFOG enables the identification of government budget allocations for defence R&D. The defence category includes R&D allocations for defence, safety, and security of the country. For earlier years, defence R&D was included in the GBARD total.

Switzerland Pharmaceutical Industry: Total Exports data was reported at 105.551 USD bn in 2021. This records an increase from the previous number of 92.816 USD bn for 2020. Switzerland Pharmaceutical Industry: Total Exports data is updated yearly, averaging 23.787 USD bn from Dec 1988 (Median) to 2021, with 34 observations. The data reached an all-time high of 105.551 USD bn in 2021 and a record low of 3.249 USD bn in 1988. Switzerland Pharmaceutical Industry: Total Exports data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Switzerland – Table CH.OECD.MSTI: Trade Statistics: OECD Member: Annual.

In Switzerland, the Business Enterprise sector comprises private enterprises only. Public enterprises are included in the Government sector.

From 2000, the Government sector no longer includes the telecommunications companies that have been privatised (Swisscom).

From 2017 onwards, GBARD data are derived from a funder-based approach (performer-based approach before 2017). The Swiss contribution to the European Space Agency is allocated to the space objective in GBARD as of 2006, while it was before included in non-oriented research programmes. From 1998, the Federal Office of Agriculture and its research institutes no longer break down their R&D by socio-economic objective but group all under 'Agriculture'. For GBARD this results in a break in series for both Agriculture and Health objectives, where half of the funds previously declared under Health are now declared under Agriculture. Also in 1998, the telecommunications field of the Federal Post office has become the private enterprise Swisscom which is no longer included under the Infrastructure objective in GBARD. Before 1994, GBARD did not include the public sector financed R&D mandates.

Morocco Market Capitalization: Casablanca Stock Exchange: BM: Pharmaceutical Industry data was reported at 0.000 MAD mn in 2017. This stayed constant from the previous number of 0.000 MAD mn for 2016. Morocco Market Capitalization: Casablanca Stock Exchange: BM: Pharmaceutical Industry data is updated yearly, averaging 0.000 MAD mn from Dec 2005 (Median) to 2017, with 13 observations. The data reached an all-time high of 1,647.745 MAD mn in 2005 and a record low of 0.000 MAD mn in 2017. Morocco Market Capitalization: Casablanca Stock Exchange: BM: Pharmaceutical Industry data remains active status in CEIC and is reported by Casablanca Stock Exchange. The data is categorized under Global Database’s Morocco – Table MA.Z003: Casablanca Stock Exchange: Market Capitalization: Annual.

Global Lipid Based Formulations Market is anticipated to grow with an impressive CAGR in the forecast period, 2023-2027, on account of growing pharmaceutical industry. Lipid Based Formulations Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2017-2027

According to Cognitive Market Research, the global Pharmaceutical Drying Equipment market size will be USD 5628.9 million in 2025. It will expand at a compound annual growth rate (CAGR) of 8.00% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 2082.6 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 1632.3 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 1350.9 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 213.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2025 to 2033.
Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 225.1 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 123.84 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
Spray category is the fastest growing segment of the Pharmaceutical Drying Equipment industry

Market Dynamics of Pharmaceutical Drying Equipment Market

Key Drivers for Pharmaceutical Drying Equipment Market

Expansion of Pharmaceutical Manufacturing Facilities to Boost Market Growth

The growing prevalence of chronic illnesses such as cancer, diabetes, and cardiovascular diseases has significantly increased the global demand for pharmaceutical products. In 2022, North America accounted for 52.3% of global pharmaceutical sales, far surpassing Europe’s 22.4%. According to IQVIA (MIDAS, May 2023), 64.4% of newly launched medicines between 2017 and 2022 were introduced in the U.S. market, compared to just 16.4% in Europe’s top five markets. The global prescription pharmaceutical market was valued at approximately €1,222,921 million (or $1,287,736 million) at ex-factory prices in 2022. North America (comprising the U.S. and Canada) maintained its position as the world’s largest pharmaceutical market, significantly ahead of Europe, China, and Japan. To address this rising demand, pharmaceutical companies are actively expanding their manufacturing capabilities worldwide. For example, Takeda Pharmaceuticals invested around USD 750 million in a new plasma-derived therapy production facility in Japan in 2023, while BeiGene launched a clinical R&D center and biologics manufacturing plant in the U.S. in July 2024. Such developments are driving the need for advanced pharmaceutical drying equipment to ensure the efficient processing of active pharmaceutical ingredients (APIs) and maintain high product quality.

https://www.efpia.eu/media/rm4kzdlx/the-pharmaceutical-industry-in-figures-2023.pdf/.//./

Rising Demand for Biopharmaceuticals and Personalized Medicine to Boost Market Growth

The biopharmaceutical sector is undergoing rapid expansion, largely fueled by the growing emphasis on personalized medicine and the increasing development of biologics. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), U.S.-based biopharmaceutical companies invested approximately $96 billion in research and development (R&D) in 2023, representing over 20% of their total sales. The industry's overall economic footprint in the U.S. is substantial. In 2022 alone, more than $25 billion in biopharmaceutical exports originated from majority foreign-owned companies operating within the country. These firms also invested nearly $26 billion in R&D during the same year. Furthermore, foreign direct investment in the U.S. pharmaceutical and medicine sector reached $503.4 billion in 2023. Biopharmaceutical products—such as vaccines, monoclonal antibodies, and hormones—demand highly specialized drying processes to ensure their stability and effectiveness. Technologies like freeze dryers and vacuum dryers are crucial for handling these sensitive compounds without degrading product quality. As the biopharmaceutical industry continues to expand, it serves as a major growth driver for the pharmaceutical drying equipment ...

Mexico MX: BERD Performed: Pharmaceutical Industry data was reported at 6.170 % in 2017. This stayed constant from the previous number of 6.170 % for 2016. Mexico MX: BERD Performed: Pharmaceutical Industry data is updated yearly, averaging 6.018 % from Dec 1994 (Median) to 2017, with 24 observations. The data reached an all-time high of 17.130 % in 2011 and a record low of 1.803 % in 1994. Mexico MX: BERD Performed: Pharmaceutical Industry data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Mexico – Table MX.OECD.MSTI: Business Enterprise Investment on Research and Development: OECD Member: Annual.

In Mexico, beginning with the 2004 data, the Business enterprise survey register was increased to include large firms not previously identified as R&D performers. The first R&D surveys based on the Frascati Manual covered the period 1992-93. Earlier data for R&D performed in the Government sector are based on national estimates and do not exactly correspond to the recommendations of the Frascati Manual.

Slovenia SI: Pharmaceutical Industry: Export Market Share data was reported at 1.108 % in 2020. This records an increase from the previous number of 0.853 % for 2019. Slovenia SI: Pharmaceutical Industry: Export Market Share data is updated yearly, averaging 0.497 % from Dec 1996 (Median) to 2020, with 25 observations. The data reached an all-time high of 1.108 % in 2020 and a record low of 0.355 % in 2002. Slovenia SI: Pharmaceutical Industry: Export Market Share data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Slovenia – Table SI.OECD.MSTI: Trade Statistics: OECD Member: Annual.

In Slovenia, some reporting units' business-financed BERD was reallocated to funds from abroad to comply with the 2015 Frascati Manual, starting in 2017. before 2014, the GERD allocation by type of R&D was estimated from the number of projects recorded in each type of R&D, and not from the actual amount of R&D expenditure (as it is the case from 2014). In 2011, the increase in R&D personnel and expenditure is notably explained by both the improvement of non-response analysis and new administrative sources to better identify R&D performers. Beginning reference year 2008, survey coverage was expanded to include some innovative companies that were not previously recognized as R&D performers.

The statistic describes the global pharmaceutical market's growth from 2008 to 2012 with a forecast from 2013 to 2017. Between the year 2010 and 2011, a growth of *** percent was recorded within the industry.

Product Market size is rising upward in the past few years And it is estimated that the market will grow significantly in the forecasted period

Snapshot img { margin: 10px !important; } Overview of the global qPCR market

According to Technavio’s market research report, the global qPCR market will grow at a CAGR of close to 8% during the forecast period. One of the key drivers stimulating the growth of this global market during the next few years will be the increasing demand for new drugs. The number of chronic diseases such as cancer is expected to rise by about 70% over the next two decades due to factors such as the increasing urbanization, sedentary lifestyle, and unbalanced diet. Around 20% of the global cancer deaths and around 70% of global lung cancer deaths are caused by the consumption of tobacco and alcohol. Also, the prevalence of autoimmune disorders such as rheumatoid arthritis, polymyalgia rheumatic, and Crohn's disease is increasing. This will drive the demand for new drugs and clinical researches. Many research applications are carried out using advanced equipment such as quantitative polymerase chain reaction (qPCR). The qPCR analysis technology provides valuable quantitative data analysis of nucleic acids as it is highly specific, sensitive, and accurate. Consequently, demand for qPCR for research as well as testing and diagnostic purposes will increase during the estimated period.

The increasing number of outsourcing activities acts as one of the key trends responsible for the growth in the qPCR market. The outsourcing of research and drug discovery and the development of contract research organization (CROs) by drug manufacturing and biotechnology companies helps vendors to reduce their expenditure on research and developmental activities. This drives the demand for qPCR technologies because CROs highly rely on this technology to develop products and conduct clinical trials.

Competitive landscape and key vendors

The qPCR market is highly fragmented due to the presence of many international and regional players in many countries. The increasing number of applications in the field of medical, diagnosis of infectious diseases, and forensics for various purposes will open growth opportunities for these vendors. These players are increasingly adopting mergers and acquisitions to increase their investment in research and developmental activities. Furthermore, vendors are also focusing on offering solutions with features such as consistent quality of data, sensitivity, high-throughput ability, ease of use, multiplexing capacity, and service and support.

Key vendors in this market are -

Agilent Technologies
Bio-Rad Laboratories
QIAGEN
Thermo Fisher Scientific

Other prominent vendors in the market include altona Diagnostics, Cepheid, Roche Diagnostics, Promega, and TATAA Biocenter.

Segmentation by application and analysis of the qPCR market

Drug discovery and development
Clinical diagnostics
Research laboratories

The drug discovery and development segment contributed to the maximum market shares during 2016. This was mainly due to the rising number of pharmaceutical companies and the demand for new drug development. The need for drug discovery and development is increasing due to the outbreak of various unknown diseases in different parts of the world. This has driven the number of pharmaceutical companies on a global level. The segment will continue to account for the largest shares during the predicted period as well since qPCR technology is widely used in various stages of drug discovery such as the study of gene expression, gene profiling, genotyping, and analysis of DNA methylation.

Segmentation by geography and analysis of the qPCR market

Americas
APAC
EMEA

Owing to the presence of developed healthcare infrastructure and many pharmaceutical companies in countries such as the US, the Americas accounted for the majority shares of the qPCR market during 2016. The rise in number of tests related to the development of new drugs and disease diagnosis that requires qPCR techniques and this will turn, fuel the demand for qPCR in this region during the next four years.

Key questions answered in the report include

What will the market size and the growth rate be in 2021?
What are the key factors driving the global qPCR market?
What are the key market trends impacting the growth of the global qPCR market?
What are the challenges to market growth?
Who are the key vendors in the global qPCR market?
What are the market opportunities and threats faced by the vendors in the global qPCR market?
What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
What are the key outcomes of the five forces analysis of the global qPCR market?

Technavio also offers customization on reports based on specific client requirement.

This upcoming industry research report on the global qPCR market offers insights into the key trends and emerging drivers influencing the growth of the lab equipment industry. Our market research reports for this industry follow a comprehensive data collec

Snapshot img { margin: 10px !important; } Overview of the global substance abuse treatment market

Market research analysts at Technavio predict that the global substance abuse treatment market will grow at a CAGR of more than 5% by 2021. The rise in government initiatives for improved awareness is identified as one of the primary growth factors for this market. Various programs and initiatives have been set up by government agencies and many organisations to increase awareness about the chronic ill-effects of substance abuse. These include initiatives taken up at work places, community programs, and technical assistance programs at local, state, and national levels. The Substance Abuse and Mental Health Services Administration (SAMHSA), a branch of the U.S Department of Health and Human Services has multiple programs to improve awareness. SAMHSA's Division of Workplace Programs (DWP) supervises programs to eradicate illicit drug use in federal workplaces and helps all workplaces become drug-free. Under this program, DWP regulates various policies for a drug-free workplace.

The consolidation of rehabilitation centers is one of the latest trends that will contribute to the growth of the market. Over the recent years, the major rehabilitation centers in the market have increasingly adopted inorganic growth strategies to expand their presence in various regions. The acquisition of smaller rehabilitation centers by the major rehab centers has resulted in the uniformity of treatment patterns and increased the capacity of rehabilitation centers. Acquisition also helped several smaller mental rehabilitation centers to expand their functionality to include treatment for substance abuse.

Competitive landscape and key vendors

The substance abuse treatment market is characterized by the presence of few key vendors and prominent vendors. The market is competitive and factors such as new drug development, technological advances to improve patient compliance, and inorganic strategies by rehabilitation centers and small vendors, will increase the level of competition among the market players.

The leading vendors in the market are -

Alkermes
Allergan
GSK
Pfizer

The other prominent vendors in the market are Accord Healthcare, Amphastar Pharmaceuticals, Apotex, BioCorRx, Cipla, Glenmark, INSYS Therapeutics, LFB Group, Lupin, Mylan Laboratories, Opiant Technologies, Sanofi Aventis, Sanquin, Sterinova, Sun Pharma, and Teva Pharmaceutical.

Segmentation by type of abuse and analysis of the substance abuse treatment market

Alcohol abuse treatment
Nicotine abuse treatment
Drug abuse treatment

During 2016, the alcohol abuse treatment segment accounted for the major shares of the substance abuse treatment market. Factors such as the increase in government initiatives, the rising awareness in developing countries, and the improved rehab facilities, will contribute to the growth of this industry segment in the coming years.

Geographical segmentation and analysis of the substance abuse treatment market

Americas



APAC
EMEA

This market study estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the market throughout the forecast period. The rise in number of people with addiction and the rise in the number of rehabilitation centers will be the major factors propeling the growth of the substance abuse treatment market in this region.

Key questions answered in the report include

What will the market size and the growth rate be in 2021?
What are the key factors driving the global substance abuse treatment market?
What are the key market trends impacting the growth of the global substance abuse treatment market?
What are the challenges to market growth?
Who are the key vendors in the global substance abuse treatment market?
What are the market opportunities and threats faced by the vendors in the global substance abuse treatment market?
Trending factors influencing the market shares of the Americas, APAC, and EMEA.
What are the key outcomes of the five forces analysis of the global substance abuse treatment market?

Technavio also offers customization on reports based on specific client requirement

Austria AT: Pharmaceutical Industry: Export Market Share data was reported at 1.837 % in 2020. This records an increase from the previous number of 1.828 % for 2019. Austria AT: Pharmaceutical Industry: Export Market Share data is updated yearly, averaging 1.645 % from Dec 1996 (Median) to 2020, with 25 observations. The data reached an all-time high of 2.118 % in 2014 and a record low of 1.338 % in 2001. Austria AT: Pharmaceutical Industry: Export Market Share data remains active status in CEIC and is reported by Organisation for Economic Co-operation and Development. The data is categorized under Global Database’s Austria – Table AT.OECD.MSTI: Trade Statistics: OECD Member: Annual.

In Austria, three large units were reclassified in the Government sector in 2016 (previously included in the business and the Higher education sectors). From 2017, government R&D support through tax incentives is reported as funds from the business sector. Beforehand, it was included in the government funding.

Since 2009, a large unit previously omitted has been included as an R&D performer in the PNP sector.

From 2007 onwards, the former 'post-secondary colleges for teacher training' ('Paedagogische Akademien') have become 'Universities of Education' and are, consequently surveyed as units of the Higher education sector (up to 2006 these units were covered in the Government sector).

In the BE sector, the 'research premium' is included in 'funds from government' beginning 2006. This measure was introduced for the first time for the calendar year 2002, and for the 2002 and 2004 data, government funding for R&D via the 'research premium' was subsumed under 'funds from enterprises'.

In 2004, Statistics Austria’s regular annual updating procedure of the R&D expenditure data resulted in revisions showing a significant increase compared to previous estimates, mainly due to the inclusion of results from the 2002 survey of the business enterprise sector.